News
AstraZeneca could spend up to $5.3 billion in a deal to develop oral medicines with CSPC Pharmaceutical. Elsewhere, Insmed ...
For the second time in nine months, a Delaware judge has sided (PDF) with Syntimmune shareholders over AstraZeneca, granting ...
VOV.VN - Prime Minister Pham Minh Chinh has proposed that AstraZeneca consider building a pharmaceutical manufacturing plant ...
Sanjeev Kumar Panchal has stepped down as Managing Director of AstraZeneca Group. The company has appointed Praveen Rao ...
AstraZeneca (LSE:AZN) recently entered into a collaborative research initiative with IonQ, AWS, and NVIDIA, focused on ...
AstraZeneca PLC ADR closed 14.46% short of its 52-week high of $87.68, which the company reached on August 30th.
An AstraZeneca Plc affiliate suffered a greater than $180 million court loss Wednesday over its lackluster efforts to ...
The thing that I worry about more than loss of exclusivity is this term that I introduced at the AACR meeting -- loss of relevancy" says Susan Galbraith, EVP of Oncology R&D at AstraZeneca.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback